Vir Biotech-GSK's COVID-19 Treatment Wins Provisional Approval In Australia

The Australian Therapeutic Goods Administration has granted provisional marketing authorization for Vir Biotechnology Inc's VIR for sotrovimab, a monoclonal antibody for COVID-19.
The approval covers adults and adolescents who do not require initiation of oxygen due to COVID-19 and are at increased risk of progression to hospitalization or death.
Vir Biotechnology developed sotrovimab in partnership with GlaxoSmithKline plc GSK.
It is authorized for emergency use in the U.S. and has received a positive scientific opinion from CHMP in the European Union.
Price Action: VIR stock is up 1.14%% at $47.00, while GSK stock is down 0.55% at $41.62 during the market session on the last check Monday.

Overview Rating:

Speculative

0100